Topics

Dinutuximab Misses Survival Endpoint in Small Cell Lung Cancer

12:22 EST 3 Feb 2020 | OncLive

The addition of dinutuximab injection to irinotecan did not improve overall survival compared with irinotecan or topotecan alone in patients with relapsed/refractory small cell lung cancer, missing the primary endpoint of the phase II/III DISTINCT trial.

Original Article: Dinutuximab Misses Survival Endpoint in Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "Dinutuximab Misses Survival Endpoint in Small Cell Lung Cancer"

Quick Search

Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...